A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Bender, David, Sill, Michael W., Lankes, Heather A., Reyes, Henry D., Darus, Christopher J., Delmore, James E., Rotmensch, Jacob, Gray, Heidi J., Mannel, Robert S., Schilder, Jeanne M., Hunter, Mark I., McCourt, Carolyn K., Samuelson, Megan I., Leslie, Kimberly K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4642817/
https://ncbi.nlm.nih.gov/pubmed/26186911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados